Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Harris

Showing results (141-150 of 145) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 145 results.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK InhibitorsHa-Soon Choi, Paul V Rucker, Zhicheng Wang, et al.
The Canadian Journal of Cardiology|June 20, 2020
Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual CareNathaniel Moulson, David Bewick, Tracy Selway, et al.
Regulatory Toxicology and Pharmacology : RTP|March 4, 2020
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationHelen Prior, Paul Baldrick, Sonja Beken, et al.
Annals of Neurology|September 27, 2018
Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasiaDavid Bergeron, Maria L Gorno-Tempini, Gil D Rabinovici, et al.
Pageof 15

Showing results (141-150 of 145) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 145 results.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK InhibitorsHa-Soon Choi, Paul V Rucker, Zhicheng Wang, et al.
The Canadian Journal of Cardiology|June 20, 2020
Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual CareNathaniel Moulson, David Bewick, Tracy Selway, et al.
Regulatory Toxicology and Pharmacology : RTP|March 4, 2020
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationHelen Prior, Paul Baldrick, Sonja Beken, et al.
Annals of Neurology|September 27, 2018
Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasiaDavid Bergeron, Maria L Gorno-Tempini, Gil D Rabinovici, et al.
Pageof 15